Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment for CD5+ B cell lymphoma

a lymphoma and cd5 technology, applied in the field of treatment of cd5 + b cell lymphoma, can solve the problems of insufficient antibody production, direct tissue infiltration of cll, and inability to produce antibodies, and achieve the effect of increasing the expression of at least one cell surface molecul

Inactive Publication Date: 2005-03-10
COLEY PHARMA GRP INC
View PDF99 Cites 52 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent describes a method of treating a type of B cell lymphoma called CD5+ B cell lymphoma by using a small molecule called an IRM (immune response modifier) to increase the expression of certain molecules on the surface of the cancer cells. This can lead to a decrease in the number of cancer cells in the peripheral blood, a reduction in the size of lymph nodes and spleenomegaly, and the resolution of nodular, erythematous lesions associated with CD5+ B cell lymphoma. The IRM can also stimulate the production of cytokines and activate specific T cells to target the cancer cells. The patent also describes a vaccine that includes isolated CD5+ B cell lymphoma cells that have been contacted with an IRM to increase the expression of cell surface molecules. Overall, the patent provides a method for treating CD5+ B cell lymphoma by targeting the cancer cells with an IRM to increase the expression of cell surface molecules and stimulate the immune system."

Problems solved by technology

Immunodeficiency is also related to inadequate antibody production by the abnormal B cells.
With advanced disease, CLL may cause damage by direct tissue infiltration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment for CD5+ B cell lymphoma
  • Treatment for CD5+ B cell lymphoma
  • Treatment for CD5+ B cell lymphoma

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of IRM1 on Costimulatory Molecule Expression by CLL Cells

CLL cells from the indicated number of patients were cultured in IRM1 (1 μg / mL) for 3-4 days, and then assayed for expression of the costimulatory molecules indicated on the x-axis (at an intensity greater than the first decade of log fluorescence) of FIG. 1A. The percentage of cells that expressed each costimulatory molecule and the mean fluorescence intensity (MFI) of expression were measured by flow cytometry. The “fold-increase” was then calculated from the ratio of these measurements to the percentage and MFI of control cells cultured without activating agents. The average and standard error of these relative increases in costimulatory molecule expression are shown in the FIG. 1A.

IRM1 has especially strong effects on CD80, CD86, and CD54 expression, with IRM1 increasing the expression of CD54, CD80, and CD86 on CLL cells from all patients studied (n=31). The effect on CD80 was greater than on CD86 (compare FIGS...

example 2

Effects of IL-2 and IRM1 on Costimulatory Molecule Expression by CLL Cells

CLL cells were isolated and cultured alone or with IL-2 (5000 U / mL), IRM1 (1 μg / mL), or both IL-2 and IRM1 for 3-4 days. The expression of CD80, CD86, CD54, and CD83 was then determined by flow cytometry. FIG. 2A shows a characteristic example. The numbers in the dot plots in the upper and lower rows are the percentages of CD80+ and CD86+ CLL cells, respectively. FIG. 2B is a graphical representation of the percentage of CLL cells expressing the different costimulatory molecules (determined by the percentage of cells with staining intensity above the first decade of log fluorescence) from the number of patients indicated in the graph legend. The average and standard error for each of these measurements are shown in the graphs. The numbers over the double-headed arrows represent the p-values for the differences between sample means. FIG. 2C is a graphical representation of the mean fluorescence index (MFI) of...

example 3

Effect of PKC Activation on Costimulatory Phenotype and T Cell Stimulatory Ability of IL-2- and IRM1-Activated CLL Cells

CLL cells were purified from individual patients and cultured alone or with IL-2, IRM1, IL-2 and IRM1, PDB, PDB and IL-2, PDB and IRM1, or PDB, IL-2, and IRM1. After 3-4 days, these cells were harvested, washed extensively, irradiated (2500 cGy) and used to stimulate allogenic or autologous T cells from CLL patients (obtained at the same time as the CLL cells and rested in culture until added to the Mixed Lymphocytic Response (MLR) assay) after 5-6 days of culture, alamar blue was added and proliferation was measured in an optical density colorimetric microplate reader at wavelengths of 540 (reduced state) and 595 (oxidized state). The difference between these readings was used as a measure of the number of viable cells in the culture. Results are shown in FIG. 3A. The results from the T cell source that exhibited the greatest stimulation (after subtraction of th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
cell surfaceaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods for increasing expression of cell surface molecules of CD5+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and / or TLR8.

Description

BACKGROUND The peripheral B cell neoplasm chronic lymphoid leukemia / small lymphocytic lymphoma represents the most common lymphoid leukemia. As the name implies, presentation can be as either leukemia or lymphoma. However, the two presentations of this neoplasm, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), are morphologically, phenotypically, and genotypically indistinguishable, differing only in the degree of peripheral blood lymphocytosis. CLL is the most common leukemia of adults in the Western world. In CLL, the peripheral blood contains small, round lymphocytes with scant cytoplasm. Involvement of the bone marrow is observed in all cases of CLL and most cases of SLL, taking the form of interstitial infiltrates or nonparatubular aggregates of small lymphocytes. The tumor cells in CLL and SLL express the pan B cell markers CD29 and CD20. In addition, CD5-a T cell marker that is expressed only on a small subset of normal B cells—is present on the tumo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4745A61K38/20A61K45/06
CPCA61K31/4745A61K38/2013A61K45/06A61K2300/00A61P7/00A61P35/00A61P35/02A61P37/04
Inventor MILLER, RICHARD L.SPANER, DAVID E.
Owner COLEY PHARMA GRP INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com